Benitec Biopharma to Participate in Upcoming Conferences in January and February
Rhea-AI Summary
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and novel genetic medicines based on their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced their participation in three upcoming conferences.
The company will attend the Muscular Dystrophy Association Gene Therapy Summit in Tucson, AZ from January 28-30, 2025, followed by the Guggenheim SMID Cap Biotech Conference in New York, NY on February 5, 2025, which will feature one-on-one meetings. Additionally, Benitec will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 2:00 PM EST, offering both a presentation and one-on-one meeting opportunities. The Oppenheimer presentation will be available via live webcast.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BNTC gained 0.28%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
HAYWARD, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences.
Muscular Dystrophy Association Gene Therapy Summit
Dates: January 28 – 30, 2025
Location: Tucson, AZ
Guggenheim SMID Cap Biotech Conference
Date: February 5, 2025
Location: New York, NY
Format: 1x1 Meetings
Oppenheimer 35th Annual Healthcare Life Sciences Conference (being held virtually)
Date: February 12, 2025
Time of Presentation: 2:00 PM EST
Format: Presentation & 1x1 Meetings
The Benitec presentation will also be available via live webcast here.
Please contact your conference representative to schedule a 1x1 meeting with Benitec management.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
FAQ
What conferences will Benitec Biopharma (BNTC) attend in early 2025?
When is Benitec Biopharma's (BNTC) presentation at the Oppenheimer Healthcare Conference?
Will Benitec's (BNTC) Oppenheimer conference presentation be available online?
What types of meeting formats are available at the conferences BNTC is attending?
What is the technology platform that Benitec (BNTC) is developing?
